Furthermore, for patients with HRD, PARPi used in the populations of ERCC1 or BRCA deficient cancers, might potentiate their therapeutic effects by regulating the signal pathway related to antitumor immunity [39, 40]. Here, ERCC1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.